ONCY

ONCOLYTICS BIOTECH INC

Tremor tracks 3 of its cancer trials.

Company-wide warning signs

These add points to every one of this company's trials.

None right now.

Trials

ONCYOncolytics Biotech
0Calm
FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer
Signing up patientsPhase 260 patientsMain results: Aug 30, 2027
ONCYOncolytics Biotech
0Calm
A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab
Running, no new patientsPhase 1/2122 patientsMain results: Jul 30, 2027
ONCYOncolytics Biotech
0Calm
A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study
Running, no new patientsPhase 248 patientsMain results: Aug 1, 2022

Key executives leaving

From the last 12 months of the company's SEC reports.

None found.

Insider trades (last 6 months)

“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.

0 sales (0 not pre-planned) · 0 purchases

No insider sales or purchases in the last 6 months.

Recent SEC filings

Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.

Money left

Coming soon: how many months of cash the company has, from its quarterly reports.